A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
NCT07221357Phase 2/3Recruiting
- Lead sponsor
- Bristol-Myers Squibb (Industry)
- Enrollment
- 990 (estimated)
- Start date
- 31 Dec 2025
- Primary completion
- 2 Feb 2030 (estimated)
- Study completion
- 11 Mar 2034
- Last update posted
- 23 Oct 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- Double
- Arms
- 5
Interventions
- Pumitamig Drug
- FOLFOX Drug
- FOLFIRI Drug
- Bevacizumab Drug
- CAPOX Drug
Conditions and primary outcome
- Untreated, Unresectable, or Metastatic Colorectal Cancer
Primary outcome
Objective Response (OR) (confirmed complete response (CR) or partial response (PR)) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 per investigator assessment (Up to 5 years); Progression Free Survival (PFS) by RECIST v1.1 per blinded independent central review (BICR) (Up to 5 years); Overall Survival (OS) (Up to 5 years)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT07221357.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT07221357 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.